Advanced maxillary sinus cancer treated with concurrent chemoradiotherapy with intra-arterial cisplatin/docetaxel and oral S-1: Own experience and literature review

Torahiko Nakashima, Ryuji Yasumatsu, Satoshi Toh, Hideki Shiratsuchi, Takeshi Kamitani, Yoshiyuki Shioyama, Katsumasa Nakamura, Shizuo Komune

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Intra-arterial (IA) chemotherapy for head and neck cancer is effective and multiple IA concurrent chemoradiation (CCRT) protocols have been reported. However, the role of IA CCRT in the multimodality treatment of head and neck cancer is still controversial. We have treated 5 cases of unresectable T4 maxillary sinus squamous cell carcinoma with IA cisplatin (CDDP) and docetaxel (DOC) and CCRT with oral S-1. We report our experience and the effectiveness and feasibility of this combination as an alternative choice of treatment for inoperable head and neck cancer. The patients received an IA infusion of CDDP (50-70 mg/m 2) and DOC (50-60 mg/m 2) through the femoral artery, followed by CCRT with oral S-1. The IA infusion was repeated up to 3 times and the radiation was dosed at up to 60-70 Gy. Complete response was achieved in 4 patients and partial response in one, giving an overall response rate of 100%. The most common grade 3 or 4 toxicities were anorexia (80%), mucositis (80%) and leukopenia (80%), all of which were manageable. CCRT with IA CDDP/DOC and oral S-1 was effective and tolerated. Although preliminary, the response rate encourages further pursuit and definitive evaluation of this combination for the treatment of inoperable advanced head and neck cancer.

Original languageEnglish
Pages (from-to)492-498
Number of pages7
JournalCase Reports in Oncology
Volume4
Issue number3
DOIs
Publication statusPublished - Sep 2011

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Advanced maxillary sinus cancer treated with concurrent chemoradiotherapy with intra-arterial cisplatin/docetaxel and oral S-1: Own experience and literature review'. Together they form a unique fingerprint.

  • Cite this